Why the study?
The relationship between serum uric acid/albumin ratio and no-reflow in STEMI patients undergoing primary PCI was unknown.
Is the serum uric acid/albumin ratio associated with angiographic no-reflow in STEMI patients undergoing primary PCI?
Is the serum uric acid/albumin ratio associated with angiographic no-reflow in STEMI patients undergoing primary PCI?
A high serum uric acid/albumin ratio is independently associated with angiographic no-reflow in STEMI patients undergoing primary PCI, performing better than either marker alone.
May aid no-reflow risk stratification in STEMI primary PCI; hypothesis-generating and requires prospective validation.
The goal of this investigation was to explore the relationship between serum uric acid/albumin ratio (UAR) and no-reflow (NR) in ST elevation myocardial infarction (STEMI) patients (n = 838) who underwent primary percutaneous coronary intervention (pPCI). Angiographic NR was defined as thrombolysis in myocardial infarction (TIMI) flows 0, 1, and 2 in the absence of coronary spasm or dissection. NR developed in 91 (10.9%) STEMI patients. Patients with NR had higher UAR and according to multivariable logistic regression models, a high UAR was an independent risk factor for NR. The area under the curve (AUC) value of the UAR was .760 (95%CI: .720-.801) in a receiver-operating characteristics curve (ROC) assessment. Notably, the UAR AUC value was greater than that of its components: albumin (AUC: .642) and serum uric acid (AUC: .637) ( P < .05 for both comparisons). The optimum UAR value in detecting NR in STEMI patients was >1.21 with a sensitivity of 82% and a specificity of 67%. This was the first study to report that the UAR was independently associated with NR in STEMI patients who underwent pPCI.
No takes yet. Share an insight, caveat, or question.
Çınar et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: